Róbert Gábor Kiss

Semmelweis University — Hungary

Medicine · Health Sciences

44h-index22.5kcitations215works14.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Antiplatelet Therapy and Cardiovascular Diseases(65), Acute Myocardial Infarction Research(46), Atrial Fibrillation Management and Outcomes(37), Lipoproteins and Cardiovascular Health(32), Coronary Interventions and Diagnostics(27)

Publications199 total

Evolocumab in Patients without a Previous Myocardial Infarction or Stroke
New England Journal of Medicine·2025· 18 cited
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk
New England Journal of Medicine·2025· 16 cited
Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function
JAMA Cardiology·2025Open Access
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
European Heart Journal·2025· 169 citedOpen Access
Initiation and Anesthetic Management of ECMO in the Adult Noncardiac Surgical Patient
AANA journal·2025
Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial
Circulation·2025· 3 cited
Long-Acting Factor XI Inhibition and Periprocedural Bleeding
Journal of the American College of Cardiology·2025· 9 citedOpen Access
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of ODYSSEY OUTCOMES
Circulation·2025· 16 citedOpen Access
BLEEDING WITH THE FXI INHIBITOR ABELACIMAB COMPARED WITH RIVAROXABAN IN OLDER INDIVIDUALS WITH ATRIAL FIBRILLATION: ANALYSIS OF THE AZALEA-TIMI 71 TRIAL
Journal of the American College of Cardiology·2025· 1 citedOpen Access
FACTOR XI INHIBITION WITH ABELACIMAB IN ATRIAL FIBRILLATION ACROSS THE SPECTRUM OF BLEEDING RISK
Journal of the American College of Cardiology·2025Open Access
DIFFERENCES IN THE APPLICATION OF GUIDELINE-DIRECTED MEDICAL THERAPY AMONG PATIENTS WITH DE NOVO AND PREVIOUSLY CONFIRMED DIAGNOSIS OF HEART FAILURE WITH REDUCED EJECTION FRACTION: REAL-WORLD EXPERIENCE OF TWO TERTIARY CARDIAC CENTERS
Journal of the American College of Cardiology·2025Open Access
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation
New England Journal of Medicine·2025· 82 cited
A kettős antitrombotikus kezelés (kis dózisú rivaroxaban + aszpirin) helye a terápiában: A Magyar Angiológiai és Érsebészeti Társaság (MAÉT), a Magyar Kardiológusok Társasága (MKT) és a Magyar Stroke Társaság (MST) közös konszenzusdokumentuma
Cardiologia Hungarica·2025Open Access
Az abciximabtól az abelacimabig : Szubjektív szörfözés a kardiológia biológiai terápiás lehetőségein és kudarcain
Cardiologia Hungarica·2025Open Access
The implementation of modern guideline-directed medical therapy among hospitalized patients with heart failure with reduced ejection fraction: real-world experience from two tertiary cardiac centers
European Heart Journal·2024
The development and long-term maintenance of heart failure with improved ejection fraction after a heart failure hospitalization: how are mortality rates affected?
European Heart Journal·2024· 1 citedOpen Access
Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary Syndrome
Journal of the American College of Cardiology·2024· 12 citedOpen Access
Dissemination of the European Society of Cardiology clinical practice guidelines into the National Societies of Cardiology Journals
European Heart Journal·2024Open Access
Gasztroenterológiai-kardiológiai konszenzus a hatékony gasztroprotekció szükségességéről antithrombotikus kezelés alkalmazásakor
Magyar Belorvosi Archívum·2024Open Access
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
European Heart Journal - Cardiovascular Pharmacotherapy·2024· 16 citedOpen Access
page 1 of 10Next →

Frequent Co-authors

Deepak L. Bhatt(15), Philippe Gabríel Steg(14), Andrzej Budaj(11), István Préda(11), Marc S. Sabatine(10), J. Wouter Jukema(9), Andreas M. Zeiher(9), Michael Szarek(9), Rafael Díaz(9), Robert Pordy(9), Gregory G. Schwartz(9), Marc P. Bonaca(8), Alexander Parkhomenko(8), Béla Merkely(8), Harvey D. White(8), Sabina A. Murphy(7), Dániel Aradi(7), Kurt Huber(7), Vera Bittner(7), Shaun G. Goodman(7)